HAL (France)open access
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis
Network-meta analysis, Encorafenib, BRAF inhibitor, Indirect comparison, Dabrafenib, 0, Metastatic melanoma, Vemurafenib
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 126730
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.